MedTrace Logo

Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer Patients

NCT00245466 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2011-05-20

Study results available
· View outcomes & findings →

Summary

To investigate the long-term safety and tolerability of repeated doses of degarelix to prostate cancer patients

Conditions

Interventions

DRUG

Degarelix

Given as a subcutaneous injection once every 4 weeks.

DRUG

Degarelix

Given as a subcutaneous injection once every 4 weeks.

DRUG

Degarelix

Given as a subcutaneous injection once every 4 weeks.

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Development Support · Ferring Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Primary Completion
2006-03-31
Completion
2006-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00245466 on ClinicalTrials.gov